Filing Details

Accession Number:
0000904454-14-000731
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-11-12 15:06:17
Reporting Period:
2014-11-12
Filing Date:
2014-11-12
Accepted Time:
2014-11-12 15:06:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1444380 Nevro Corp NVRO Surgical & Medical Instruments & Apparatus (3841) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
200406 Johnson & Johnson One Johnson &Amp; Johnson Plaza
New Brunswick NJ 08933
No No Yes No
924020 Johnson & Johnson Development Corp Et Al One Johnson &Amp; Johnson Plaza
New Brunswick NJ 08933
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-11-12 3,037,005 $0.00 3,037,005 No 4 C Indirect Johnson & Johnson Development Corporation
Common Stock Acquisiton 2014-11-12 40,000 $18.00 3,077,005 No 4 P Indirect By Johnson & Johnson Development Corporation
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect Johnson & Johnson Development Corporation
No 4 P Indirect By Johnson & Johnson Development Corporation
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Convertible Preferred Stock Disposition 2014-11-12 2,790,178 $0.00 2,790,178 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2014-11-12 246,827 $0.00 246,827 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
  2. Immediately prior to the closing of the Issuer's initial public offering each outstanding share of Preferred Stock automatically converted into Common Stock, on a 1-to-1 basis, for no additional consideration. There was no expiration applicable to the Preferred Stock.